ARVINAS, INC. (ARVN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US04335A1051
ARVINAS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 262.60 m USD |
| Operating income | -118.50 m USD |
| EBIT | -118.90 m USD |
| Net income | -80.80 m USD |
| Diluted EPS – continuing operations | -1.14 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ARVINAS, INC.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
More stocks
- FTAI Infrastructure Inc. (FIP)
- Sichuan Shengda Forestry Industry Co Ltd (002259.SZ)
- Shanghai New Huang Pu Real Estate Co Ltd (600638.SS)
- Shanghai Dragon Corp (600630.SS)
- Stx Engine (077970.KS)
- G2GBIO Inc. (456160.KQ)
- Guangdong Decro Film New (001378.SZ)
- Commercial Bancgroup, Inc. (CBK)
- Scinai Immunotherapeutics Ltd. (SCNI)
- Oriental Times Media Corp (002175.SZ)
- Tengda Construction Group Co Ltd (600512.SS)
- Dutch Lady Milk Industries Bhd (3026.KL)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.